Annika Loftenius

Phase I clinical evaluation of ^99mTc-labeled Affibody molecule for imaging HER2 expression in breast cancer

Olga Bragina, Anstasiya Rybina, Roman Zelchan et al. · Theranostics · 2023 · 40 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake

Maryam Oroujeni, Sara S. Rinne, Anzhelika Vorobyeva et al. · International Journal of Molecular Sciences · 2021 · 31 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab

Yongsheng Liu, Tianqi Xu, Anzhelika Vorobyeva et al. · Cancers · 2023 · 23 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain

Yongsheng Liu, Anzhelika Vorobyeva, Tianqi Xu et al. · Pharmaceutics · 2021 · 18 citations · Full text

Pharmacy, Oncology, Pharmaceutics +17

Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile

Yongsheng Liu, Maryam Oroujeni, Yunqi Liao et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2024 · 11 citations · Full text

Pharmacy, Oncology, Pharmaceutics +17